Physician profile
Sarah E Hall
NPI 1013368448
$1,340.40
in general payments reported to CMS, 2019-2025
18 companies · $64.35 in 2025
The $64.35 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $477 · 2023: $408 · 2024: $161 · 2025: $64.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $418.68 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abbvie INC. | $362.43 | 2021-2025 | |
| Indivior INC. | $78.66 | 2022-2025 | Sublocade |
| Lilly USA, LLC | $77.08 | 2021-2024 | Mounjaro, Zepbound |
| Supernus Pharmaceuticals, INC. | $54.47 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.19 | 2024 | Farxiga |
| Pfizer INC. | $41.58 | 2021-2022 | |
| Tris Pharma INC | $36.09 | 2023 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $35.02 | 2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $32.67 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.95 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.79 | 2021 | |
| Novo Nordisk INC | $19.29 | 2023 | Rybelsus, Ozempic |
| Amgen INC. | $18.06 | 2024 | Repatha, Otezla |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $17.68 | 2022 | |
| Braeburn INC. | $14.40 | 2023 | Brixadi |
| Astellas Pharma US INC | $14.15 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.